SoftOx Defense Solutions AS: HPRA Approves SIS-02 Phase 1 Trial, Strengthening Dual-Use and Preparedness Strategy

25 Feb 2026 08:00 CET

Oslo / Dublin: SoftOx Defense Solutions AS (“SoftOx”) announces that the Health
Products Regulatory Authority (HPRA) in Ireland has approved the Company’s
clinical trial application (CTA) for the SIS-02 Phase 1 clinical study in
healthy volunteers.

The SIS-02 study will evaluate the safety, tolerability, and pulmonary exposure
profile of SoftOx’s inhalation solution. The approval represents a critical
execution milestone, transitioning SIS into controlled human testing and
establishing the human safety and dosing foundation required for both civilian
development and preparedness-oriented pathways, including defence and biological
countermeasure applications.

Strategic and Scientific Significance
Approval of SIS-02 confirms the readiness of SoftOx’s inhalation platform for
human clinical evaluation and validates the Company’s development capabilities
across GMP manufacturing, regulatory documentation, and clinical execution.

Conducting SIS-02 enables SoftOx to:
Establish robust human safety and tolerability data
Characterize pulmonary dose and exposure
Generate foundational human data required for emergency-use and
preparedness-relevant development routes

Business Implications: Parallel Clinical and Preparedness Execution
With the approval of SIS-02, SoftOx now has two regulatory-approved clinical
trials, following the previously announced Phase 2a approval by the Danish
Medicines Agency.

This positions the Company to move from sequential development into parallel
execution, including:
Phase 1 human safety and exposure (Ireland)
Phase 2a dose escalation and early proof-of-concept in cystic fibrosis (Denmark)


The establishment of human safety and dosing data across these programs also
enables SoftOx to consider programs for Dual-use and preparedness-oriented
development activities in parallel with clinical execution.

Value and Relevance for Dual-Use and Biodefence Preparedness
SoftOx’s SIS platform is being developed as a broad-spectrum, non-antibiotic
inhaled therapeutic with attributes relevant to modern biodefence and medical
countermeasure strategies, including:
Activity against bacteria, viruses, and fungi addressing diverse airborne
biological threats
Low risk of resistance development, preserving long-term effectiveness and
deployment flexibility
Local airway administration enabling rapid onset at the primary site of exposure
Scalable manufacturing and formulation stability are potentially compatible with
stockpiling and rapid deployment frameworks

These attributes create potential optionality for future preparedness-oriented
development pathways, contingent upon clinical validation and strategic or
non-dilutive funding support.

If pursued, this would enable the SIS platform to address both chronic
respiratory disease and defence-relevant biological threats within national
resilience and pandemic response architectures.

While the dual-use profile thus enhances the long-term commercial flexibility of
the platform, it does not alter the current clinical development focus, nor
jeopardize the financial discipline applied in execution.

CEO, Thomas Bjarnsholt, comments:
“The approval of SIS-02 by HPRA in Ireland is a key execution milestone for
SoftOx. It establishes the human safety and dosing foundation of our inhalation
platform and, together with our already approved Phase 2a program, enables us to
advance civilian development while progressing preparedness-oriented and
defence-relevant applications in parallel.”

Next step
Following approval, SoftOx will proceed with clinical site initiation and dosing
of healthy volunteers in accordance with the approved protocol.

For further information, please contact:
Ulrik Spork, Chairman of the Board, SoftOx Solutions AS, +45 31 38 83 87
Thomas Bjarnsholt, CEO, SoftOx Solutions AS, +45 20 65 98 88
Mail: ir@soft-ox.com

About SoftOx Solutions AS
SoftOx Solutions AS (ticker: SOFTX) is a clinical-stage pharmaceutical company
listed on Euronext Growth Oslo. The Company develops innovative, non-antibiotic
antimicrobial inhalation therapies targeting bacteria, viruses, and fungi, with
applications spanning civilian healthcare, public health preparedness, and
future biological countermeasures.

More information:
Access the news on Oslo Bors NewsWeb site